Login to Your Account

Clinic Roundup

Tuesday, May 3, 2011
Agile Therapeutics Inc., of Princeton, N.J., presented and published Phase II data showing that AG200-15 delivers a daily estrogen dose of 30 mcg, is well tolerated and did not cause differences in ovulation in obese vs. nonobese women. The data were presented at the American College of Obstetricians and Gynecologists' 59th Annual Clinical Meeting and published in the journal Hormone Molecular Biology and Clinical Investigation.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription